Sophie Millar completed her doctorate studies in vascular and cannabinoid based medicines at the University of Nottingham, and is currently based in Brussels undertaking a Traineeship at the European Parliament Research Services. She is interested in communicating topics broadly related to drug development and health, and has contributed to a number of STEM outreach activities and articles.
Contributor: Sophie Millar
A scientist’s opinion : Interview with Professor PierFranco Conte about animal testing
Animal testing, a scientist’s opinion Interview with Professor PierFranco Conte, Full Professor of Oncology at the University of Padova and Director of the Division of Medical Oncology 2 at the Istituto Oncologico Veneto in Padova. In your opinion, why is animal use for scientific purposes still so common place? Are animal models still essential for ...
A scientist’s opinion : Interview with Dr Jason Johnson about animal testing
Interview with Dr Jason Johnson, British Heart Foundation Senior Research Fellow, Associate Professor of Cardiovascular Pathology, and leads the Laboratory of Cardiovascular Pathology at Bristol Medical School, University of Bristol. As a scientist, in general do you find that the 3Rs concept is something that is routinely thought of when discussing experimental plans, or is ...
A scientist’s opinion : Interview with Aroon Hingorani about re-engineering pharmaceutical research
Interview with Aroon Hingorani, Professor of Genetic Epidemiology at University College London about Re-engineering pharmaceutical research. Could you speculate what you think are the biggest causes of drug failure? Aroon Hingorani: It is well recognised that the number one cause for drug failure is a lack of efficacy of the drug in the intended indication, ...
A scientist’s opinion : Interview with Dr Denis Lacombe about re-engineering pharmaceutical research
Interview with Dr Denis Lacombe, Director General of the European Organisation for Research and Treatment of Cancer (EORTC) about Re-engineering pharmaceutical research. Can you tell me a bit about the European Organisation for Research and Treatment of Cancer (EORTC)? Denis Lacombe: We are a non-governmental, not-for-profit organisation established for 60 years, focusing on survival and ...
Re-engineering pharmaceutical research for better patient outcomes
A so-called ‘productivity crisis’ has been ascribed to the pharmaceutical research and development industry. Despite increases in investment and funding, this has not corresponded to increases in the approval of novel drugs. Why do so many drugs fail to receive approval, and what other means should we be focusing on for the benefit of patients?
A scientist’s opinion : Interview with Dr Síle Lane about re-engineering pharmaceutical research
Interview with Dr Síle Lane, head of international campaigns and policy at Sense About Science, about Re-engineering pharmaceutical research. Undisclosed clinical trial results are unfortunately common - how does this impact progression in research and treatment? Síle Lane: When results from clinical trials aren’t published it means the same research can get repeated unnecessarily. This ...
